Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 20, 2020
Deals
After three-target Lilly deal, Precision BioSciences hunting for more partnerships
With $135M up front, Lilly deal unlocks value from biotech’s ARCUS genome-editing tech
BioCentury | Jun 27, 2020
Deals
Who’ll buy uniQure now?
Even without its lead hemophilia program, the gene therapy company could make for an attractive takeout target
BioCentury | Sep 7, 2019
Product Development
Regeneron’s evinacumab data could make it the therapy of choice in HoFH
Better efficacy and safety could make Regeneron’s evinacumab the standard of care for HoFH
BioCentury | Jun 17, 2019
Company News
Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model
BioCentury | Jul 20, 2018
Regulation
FDA’s positive reinforcement
How FDA’s gene therapy guidances reinforce the paths of the most advanced candidates
Items per page:
1 - 10 of 140